GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Epigenomics AG (OTCPK:EPGNY) » Definitions » EV-to-EBIT

Epigenomics AG (Epigenomics AG) EV-to-EBIT : -0.25 (As of Apr. 25, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Epigenomics AG EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Epigenomics AG's Enterprise Value is $4.40 Mil. Epigenomics AG's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was $-17.25 Mil. Therefore, Epigenomics AG's EV-to-EBIT for today is -0.25.

The historical rank and industry rank for Epigenomics AG's EV-to-EBIT or its related term are showing as below:

EPGNY' s EV-to-EBIT Range Over the Past 10 Years
Min: -15.68   Med: -4.42   Max: 7.14
Current: 0.12

During the past 13 years, the highest EV-to-EBIT of Epigenomics AG was 7.14. The lowest was -15.68. And the median was -4.42.

EPGNY's EV-to-EBIT is ranked better than
98.13% of 107 companies
in the Medical Diagnostics & Research industry
Industry Median: 20.2 vs EPGNY: 0.12

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Epigenomics AG's Enterprise Value for the quarter that ended in Jun. 2023 was $0.00 Mil. Epigenomics AG's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was $-17.25 Mil. Epigenomics AG's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was %.


Epigenomics AG EV-to-EBIT Historical Data

The historical data trend for Epigenomics AG's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Epigenomics AG EV-to-EBIT Chart

Epigenomics AG Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.40 -3.48 -1.33 5.17 0.20

Epigenomics AG Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.49 1.33 0.20 0.27 -

Competitive Comparison of Epigenomics AG's EV-to-EBIT

For the Diagnostics & Research subindustry, Epigenomics AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Epigenomics AG's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Epigenomics AG's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Epigenomics AG's EV-to-EBIT falls into.



Epigenomics AG EV-to-EBIT Calculation

Epigenomics AG's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=4.399/-17.252
=-0.25

Epigenomics AG's current Enterprise Value is $4.40 Mil.
Epigenomics AG's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-17.25 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Epigenomics AG  (OTCPK:EPGNY) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Epigenomics AG's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jun. 2023 ) =EBIT / Enterprise Value (Q: Jun. 2023 )
=-17.252/0
= %

Epigenomics AG's Enterprise Value for the quarter that ended in Jun. 2023 was $0.00 Mil.
Epigenomics AG's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-17.25 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Epigenomics AG EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Epigenomics AG's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Epigenomics AG (Epigenomics AG) Business Description

Traded in Other Exchanges
Address
Geneststrasse 5, Berlin, BB, DEU, 10829
Epigenomics AG is a molecular diagnostics company, that focuses on developing and commercializing in vitro diagnostic liquid biopsy tests for the screening, early detection, and diagnosis of cancer. The company develops and markets procedures and devices for the production in quantity of particular epigenetic parameters such as DNA methylation patterns as well as the information technology bases necessary for their procurement and evaluation. It is engaged in the development of novel molecular diagnostic products for cancer. The company products include Epi proColon, Epi BiSKit, HCCBloodTest, and Epi proLung. The company operates in Europe, Asia, and North America, majority of its revenue derives from Asia.

Epigenomics AG (Epigenomics AG) Headlines